drugset / Trial / NCT01866098

Naltrexone for Antipsychotic-Induced Weight Gain

NCT01866098

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to look at the effects of naltrexone on weight loss in individuals treated with antipsychotic medications. Naltrexone is an FDA approved medication for the management of alcohol dependence and drug dependence, but has not been fully evaluated for its effect on weight loss in individuals with severe mental illness (i.e. schizophrenia, schizoaffective disorder, bipolar disorder etc.) The purpose of this study is to find out how effective two different doses of oral naltrexone is on reducing body weight when compared to placebo (an inactive substance or "sugar pill").

Timeline

Start
2013-05
Primary completion
2019-04-07
Completion
2019-04-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Naltrexone Small molecule 25 mg Oral
Subject Naltrexone Small molecule 50 mg Oral